The objective of this research was to investigate health technology assessments (HTAs) for rheumatoid arthritis (RA) drugs, tumor necrosis factor (TNF) drugs, and disease-modifying,
anti-rheumatic drugs (DMARDs), and their comparators to determine how the HTA decisions correlate with subpopulations and RA severity. This association makes an important contribution to the understanding of market entry.
Severe RA was reviewed 30 times, but usually not using biologic drugs as the comparators. Since all severe RA drugs in these reviews are biologics, it appears that the clinical hurdle for RA is low. Moreover, a second barrier may emerge to clinical trials in moderate-to-severe RA when biosimilar infliximab is reviewed by HTAs in the EU.
Original research presented at ISPOR 2015 in Philadelphia.